Scarica l'app Stockscreener
448.90
1.12%
-5.074
Dopo l'orario di chiusura:
447.00
-1.896
-0.42%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALNY Giù?
Forum
Previsione
Precedente Chiudi:
$453.97
Aprire:
$453.87
Volume 24 ore:
889.21K
Relative Volume:
0.81
Capitalizzazione di mercato:
$58.84B
Reddito:
$3.21B
Utile/perdita netta:
$43.57M
Rapporto P/E:
1,866.51
EPS:
0.2405
Flusso di cassa netto:
$221.36M
1 W Prestazione:
+1.40%
1M Prestazione:
-4.36%
6M Prestazione:
+67.78%
1 anno Prestazione:
+74.05%
Intervallo 1D:
$448.28
$461.96
Intervallo di 1 settimana:
$440.93
$461.96
Portata 52W:
$205.87
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Nome
Alnylam Pharmaceuticals Inc
Settore
Industria
Telefono
(617) 551-8200
Indirizzo
675 WEST KENDALL STREET, CAMBRIDGE, MA
Confronta ALNY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
448.90 | 59.98B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.15 | 110.25B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
693.50 | 73.04B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
907.98 | 54.90B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.22 | 40.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-04 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-08-04 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | Ripresa | Raymond James | Outperform |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-03-31 | Iniziato | Redburn Atlantic | Buy |
| 2025-03-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-11-12 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-08-16 | Aggiornamento | Goldman | Neutral → Buy |
| 2024-02-16 | Downgrade | Goldman | Buy → Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-12-08 | Iniziato | Wells Fargo | Equal Weight |
| 2023-10-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-09-29 | Iniziato | Raymond James | Outperform |
| 2023-05-05 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | Iniziato | SMBC Nikko | Neutral |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Buy |
| 2022-09-09 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-27 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-06-07 | Iniziato | William Blair | Outperform |
| 2022-04-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | Iniziato | Citigroup | Buy |
| 2022-02-03 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-01-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | Aggiornamento | Goldman | Neutral → Buy |
| 2021-11-22 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-10-04 | Aggiornamento | UBS | Neutral → Buy |
| 2021-08-04 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-02-12 | Downgrade | Citigroup | Buy → Neutral |
| 2021-02-12 | Reiterato | H.C. Wainwright | Buy |
| 2021-01-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | Ripresa | Berenberg | Hold |
| 2020-09-08 | Iniziato | Citigroup | Buy |
| 2020-08-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-04-24 | Ripresa | Evercore ISI | Outperform |
| 2020-03-19 | Iniziato | Berenberg | Buy |
| 2019-12-19 | Reiterato | Chardan Capital Markets | Buy |
| 2019-11-20 | Iniziato | Oppenheimer | Outperform |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-05-23 | Ripresa | Goldman | Neutral |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-03-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-03-05 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | Iniziato | UBS | Neutral |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-08-13 | Reiterato | Stifel | Buy |
| 2018-08-07 | Aggiornamento | Stifel | Hold → Buy |
| 2018-05-04 | Reiterato | Stifel | Hold |
| 2018-03-28 | Iniziato | Evercore ISI | In-line |
Mostra tutto
Alnylam Pharmaceuticals Inc Borsa (ALNY) Ultime notizie
Cardiovascular Biologics Market Expected to Reach USD 4.23 Billion by 2033 Amid Advances in RNA and Biologic Therapies | DataM Intelligence - Yahoo Finance
Is Amyloid Regression and Kidney Preservation Data From HELIOS-B Shifting the Investment Case for Alnylam (ALNY)? - simplywall.st
Is Alnylam Pharmaceuticals Inc. (DUL) stock a fit for income portfoliosWeekly Trade Review & Weekly Watchlist for Hot Stocks - newser.com
How Recent Developments Are Shaping the Alnylam Pharmaceuticals Investment Story - Yahoo Finance
How Alnylam Pharmaceuticals Inc. (DUL) stock reacts to fiscal policiesQuarterly Investment Review & Low Risk Investment Opportunities - newser.com
Can Alnylam Pharmaceuticals Inc. (DUL) stock sustain revenue momentumQuarterly Risk Review & Weekly Top Gainers Trade List - newser.com
Will Alnylam Pharmaceuticals Inc. continue its uptrendJuly 2025 Trends & Precise Trade Entry Recommendations - newser.com
Regression analysis insights on Alnylam Pharmaceuticals Inc. performance - newser.com
Published on: 2025-11-14 10:35:32 - newser.com
Using data filters to optimize entry into Alnylam Pharmaceuticals Inc.Market Risk Analysis & Accurate Entry and Exit Point Alerts - newser.com
Alnylam Pharmaceuticals (ALNY) Surged on Strong Growth and Optimistic Revenue Outlook - Insider Monkey
RNAi looked doomed to fail — until Alnylam’s science chief found a way - PharmaVoice
What RSI levels show for Alnylam Pharmaceuticals Inc. (DUL) stock2025 Macro Impact & Short-Term High Return Strategies - newser.com
How risky is Alnylam Pharmaceuticals Inc. (DUL) stock compared to peersPortfolio Update Report & Long-Term Safe Investment Plans - newser.com
Published on: 2025-11-13 01:17:44 - newser.com
Has Alnylam Pharmaceuticals Inc. found a price floorWeekly Risk Summary & Smart Allocation Stock Reports - newser.com
Can Alnylam Pharmaceuticals Inc. (DUL) stock sustain institutional flows2025 Breakouts & Breakdowns & Fast Gain Swing Trade Alerts - newser.com
Novo Nordisk's $100 Million Coramitug Shows Promise In Reducing Heart Failure Biomarker - Benzinga
What data driven models say about Alnylam Pharmaceuticals Inc.’s futureWeekly Stock Summary & High Accuracy Investment Entry Signals - newser.com
Wells Fargo Raises Price Target for Alnylam Pharmaceuticals (ALN - GuruFocus
How dovish Fed policy supports Alnylam Pharmaceuticals Inc. (DUL) stockMarket Movement Recap & High Accuracy Swing Entry Alerts - newser.com
Wells Fargo Raises Price Target for Alnylam Pharmaceuticals (ALNY) | ALNY Stock News - GuruFocus
Got $5,000? 3 Top Growth Stocks to Buy That Could Double Your Money - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Alnylam Pharma (ALNY) and Insulet (PODD) - The Globe and Mail
ALNY: Cardiomyopathy launch accelerates growth as pipeline and new tissue programs drive 2030 vision - TradingView
Alnylam at UBS Healthcare: Strategic Insights on Growth and Innovation By Investing.com - Investing.com UK
Transcript : Alnylam Pharmaceuticals, Inc. Presents at UBS Global Healthcare Conference 2025, Nov-10-2025 10 - MarketScreener
Is Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) 19% ROE Better Than Average? - 富途牛牛
Why global investors buy Alnylam Pharmaceuticals Inc. (DUL) stockJuly 2025 Big Picture & Trade Opportunity Analysis - newser.com
Alnylam (ALNY) Reports Positive Results from HELIOS-B Phase 3 St - GuruFocus
Alnylam announces results from post hoc analyses of HELIOS-B Phase 3 study - TipRanks
Is Alnylam Pharmaceuticals Inc. stock dividend yield sustainableJuly 2025 Fed Impact & Low Drawdown Investment Ideas - newser.com
Alnylam Pharmaceuticals (ALNY): Assessing Valuation Following New HELIOS-B Data and Upbeat Financial Results - simplywall.st
Alnylam Pharmaceuticals Inc says amyloid regression in 22% of vutrisiran-treated patients - MarketScreener
New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM - Business Wire
Here's How Much $1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth Today - Sahm
A Closer Look at Alnylam Pharmaceuticals (ALNY) Valuation Following Improved Earnings and Raised Revenue Guidance - Yahoo Finance
How Investors May Respond To Alnylam Pharmaceuticals (ALNY) Surging Revenue and Raised 2025 Guidance - simplywall.st
Alnylam Pharmaceuticals Scores Relative Strength Rating Upgrade - Investor's Business Daily
Alnylam Pharmaceuticals Inc Azioni (ALNY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Alnylam Pharmaceuticals Inc Azioni (ALNY) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Poulton Jeffrey V. | EVP, Chief Financial Officer |
Oct 02 '25 |
Sale |
452.05 |
3,821 |
1,727,284 |
54,052 |
| Greenstreet Yvonne | Chief Executive Officer |
Oct 02 '25 |
Sale |
452.05 |
8,924 |
4,034,085 |
65,409 |
| Tanguler Tolga | EVP, Chief Commercial Officer |
Oct 02 '25 |
Sale |
452.05 |
1,405 |
635,126 |
27,438 |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research |
Oct 02 '25 |
Sale |
452.05 |
2,441 |
1,103,451 |
25,231 |
| Garg Pushkal | EVP Chief R&D |
Oct 03 '25 |
Sale |
451.48 |
3,022 |
1,364,387 |
20,221 |
| Garg Pushkal | EVP Chief R&D |
Oct 02 '25 |
Sale |
452.05 |
2,937 |
1,327,675 |
23,243 |
1.82%
0.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):